Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer

The purpose of this study is to compare the efficacy and safety of nab-paclitaxel with solvent-based taxanes as first-line treatment for patients with advanced primary epithelial ovarian cancer (EOC), primary peritoneal carcinoma or fallopian tube carcinoma.

Trial Details

NCT ID
NCT05737303
Phase
PHASE3
Sponsor
Women's Hospital School Of Medicine Zhejiang University
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • nab-paclitaxel combined with carboplatin
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Ji'nan, Shandong, China
  • Hangzhou, Zhejiang, China|30.29365,120.16142
  • Hangzhou, Zhejiang, China|30.29365,120.16142
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Epithelial ovarian cancer/tubal cancer/peritoneal cancer was diagnosed by histopathology or hydroexfoliation cytopathology of the chest and abdomen…
  • Physical condition Eastern Cooperative Oncology Group PS score: 0-2 points
  • Participants who had not participated in other drug clinical trials within 4 weeks prior to enrollment
  • Written informed consent

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →